-

Dr. Frank Luh to Speak at ISPE LA Executive Night 2025
Dr. Frank Luh, CEO of the Sino-American Cancer Foundation (SACF), will speak at the ISPE Greater Los Angeles Chapter’s Executive Night 2025, hosted by Takeda in March 2025.A leader in…
-

laura biganzoli’s Latest Contributions to Breast Cancer & Geriatric Oncology
Dr. laura biganzoli continues to drive impactful research in breast cancer and geriatric oncology.In September 2024, she co-authored a study in the New England Journal of Medicine showing that trastuzumab…
-

Dr. Matti Aapro’s Latest Contributions to Supportive Cancer Care & Global Oncology
Dr. Matti Aapro continues to shape oncology with his latest work. In February 2025, he co-authored the MASCC antiemetic consensus recommendations in Supportive Care in Cancer, offering alternative regimens for…
-

RIGHT Choice Trial: Ribociclib + Endocrine Therapy vs. Chemotherapy in HR+/HER2– Advanced Breast Cancer
In August 2024, Dr. Nagi El Saghir and colleagues published a key subgroup analysis from the RIGHT Choice Trial, comparing first-line ribociclib (RIB) plus endocrine therapy (ET) to combination chemotherapy…
-

Dr. Hua Zhong and Dr. Baohui Han on the Efficacy and Safety of Sacituzumab Govitecan in Extensive-Stage Small Cell Lung Cancer
The rapid advancements in modern oncology have introduced numerous breakthrough treatment options for lung cancer, making it one of the fastest-evolving solid tumors. To help clinicians gain an in-depth and comprehensive understanding of major developments in this field, Oncology Frontier has collaborated with Dr. Hua Zhong and Dr. Baohui Han from the Department of Respiratory…
-

ASCO GI 2025 | Dr. Anna Dorothea Wagner:Dual-Target Therapy Shows No Survival Benefit in HER2-Positive Gastric Cancer
The 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI 2025) successfully concluded on January 25. One of the most closely watched presentations at the conference was the release of results from the EORTC-1203—INNOVATION trial (Abstract LBA331), capturing the attention of oncologists worldwide. Oncology Frontier had the exclusive opportunity to interview Dr. Anna…

